Livercancer | People | Principal Investigators

Scientific Vita

Contact

Info

Prof. Dr.

Michael Bitzer

Project: C02

Academic Education and Scientific Degrees

2011

Board Certification “Infectious Diseases”

2010

Board Certification “Palliative Care”

2007

Board Certification “Gastroenterology”, Associate Professor of the Medical Faculty, Eberhard Karls University Tübingen

2004

Venia legendi, Internal Medicine, Eberhard Karls University Tübingen

2003

Board Certification “Intensive Care Medicine”

2002

Board Certification “Internal Medicine”

1995

Medical Approbation by the State of Baden Württemberg

1994

Doctor of Medicine, Dept. of Hematology & Oncology, Eberhard Karls University Tübingen

1987-1994

Medical School, University of Tübingen and University of Colorado, Denver, USA

Professional Career

Since 2012

Deputy Director, Dept. Gastroenterology, Hepatology, and Infectiology, Tübingen Since 2010 Member of the “Habilitationsausschuss” at the Medical Faculty Tübingen

Since 2004

Consultant in Internal Medicine (Oberarzt), Dept. Internal Medicine I, Eberhard Karls University Tübingen

2001-2003

Intensive Care Medicine Fellowship, Eberhard Karls University Tübingen

1996-2002

Internal Medicine Fellowship, Eberhard Karls University Tübingen

1994-1995

Postdoctoral Fellow Max-Planck-Institute for Biochemistry, Department Virology, Martinsried

Address: Medical University Hospital
Department of Internal Medicine I
Otfried-Müller-Str. 10
72070 Tübingen
Phone: +49/7071/298 0583
eMail: michael.bitzer@uni-tuebingen.de

Awards and Appointments

Since 2019

Member of the Steering Committee of the German Guidelines for diagnosis and treatment of hepatocellular carcinoma and cholangiocarcinoma

2019

Otto Porges Award of the Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS)

2007

Award of the Rector of the Eberhard Karls University: Supervision for the best doctoral thesis in Medicine

2006

Science Award of the German Working Group on Oncology (AIO)

2005

Novartis Award for Research, 18th Symposium on pediatric Surgical Research

2003

Award from the Southwest-German Society of Internal Medicine

2002

European Society of Gene Therapy (ESGT) Grant Award, Annual Meeting, Antibes

1995

Young Scientist Research Prize, 4th United European Gastroenterology Week

Others

Since 2019

Speaker of the working group for harmonization of Molecular Tumor Boards within the Centers for Personalized Medicine in Baden Württemberg

Since 2018

Protocol development and PI of clinical study „Fingerprint Characterization of Sorafenib treated HCC“ of the BMBF-funded e:Med program (NCT03958669)

Since 2014

Editorial Board Member „Scientific Reports“

2008-2013

Protocol development and PI of the international multicenter Phase I/II SHELTER- Study in HCC (NCT00943449)

2006-2019

Elected Member of the Faculty Council, Medical Faculty Tübingen

Patents

Patent 10 2010 018 961

Genetisch modifiziertes Paramyxovirus zur Behandlung von Tumorerkrankungen

Publications

Bitzer M, Ostermann L, Horger M, Biskup S, Schulze M, Ruhm K, Hilke F, Öner Ö, Nikolaou K, Schroeder C, Riess O, Fend F, Zips D, Hinterleitner M, Zender L, Tabatabai G, Beha J, Malek NP. Next-generation sequencing of advanced GI tumors reveals individual treatment options. JCO Prec Oncol 2020;4:258-271.

Frey N, Venturelli S, Zender L, Bitzer M. Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics. Nat Rev Gastroenterol Hepatol 2018;15:81-95.

Lauer UM, Schell M, Beil J, Berchtold S, Koppenhöfer U, Glatzle J, Königsrainer A, Möhle R, Nann D, Fend F, Pfannenberg C, Bitzer M, Malek NP. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis. Clin Cancer Res 2018;24:4388-4398.

Bitzer M, Horger M, Giannini EG, Ganten TM, Wörns MA, Siveke JT, Dollinger MM, Gerken G, Scheulen ME, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek NP, Holzapfel J, Herz T, Ammendola AS, Pegoraro S, Hauns B, Mais A, Lauer UM, Henning SW, Hentsch B. Resminostat in combination with sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER Study. J Hepatol 2016;65:280-8.

Venturelli S, Belz RG, Kämper A, Berger A, von Horn K, Wegner A, Böcker A, Zabulon G, Langenecker T, Kohlbacher O, Barneche F, Weigel D, Lauer UM*, Bitzer M*, Becker C*. Plants Release Precursors of Histone Deacetylase Inhibitors to Suppress Growth of Competitors. Plant Cell 2015;27:3175-89. *Equal contribution.

Zimmermann M, Armeanu-Ebinger S, Bossow S, Lampe J, Smirnow I, Schenk A, Lange S, Weiss TS, Neubert W, Lauer UM, Bitzer M. Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors. PLoS One 2014;9:e90508.

Weiland T, Lampe J, Essmann F, Venturelli S, Berger A, Bossow S, Berchtold S, Schulze-Osthoff K, Lauer UM, Bitzer M. Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses. Int J Cancer 2014;134:235-43.

Venturelli S, Berger A, Weiland T, Zimmermann M, Häcker S, Peter C, Wesselborg S, Königsrainer A, Weiss TS, Gregor M, Fulda S, Lauer UM, Bitzer M. Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulation. Gut 2011;60:156-65.

Pathil A, Armeanu S, Venturelli S, Mascagni P, Weiss TS, Gregor M, Lauer UM, Bitzer M. Hepatology. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology 2006;43:425-34.

Armeanu S, Pathil A, Venturelli S, Mascagni P, Weiss TS, Göttlicher M, Gregor M, Lauer UM, Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 2005;42:210-7.

Publications